Management of Refractory ITP
Introduction to Refractory ITP Management
- The American Society of Hematology recommends splenectomy as the next definitive treatment option for patients with ITP refractory to steroids, rituximab, and TPO-agonists, as it provides the highest durable response rate (60-70% at 5+ years) and represents the only potentially curative intervention remaining 1
Assessment and Preparation
- Before proceeding with further therapy, it is essential to confirm true refractoriness by ensuring adequate trials of steroids for at least 4-6 weeks, rituximab at standard dosing, and TPO-agonists at maximum doses for at least 4 weeks 2
- Complete immunizations, including pneumococcal, meningococcal, and Haemophilus influenzae type B vaccines, at least 2 weeks prior to splenectomy 1
Surgical Intervention
- Splenectomy achieves an initial response in 80-85% of patients with sustained remission in 60-70% at 5+ years, and is considered the gold standard for multi-refractory ITP 1, 5
- A laparoscopic approach is recommended when feasible, as it reduces complications and mortality 5
Medical Management
- Fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, is a recommended first alternative for splenectomy-ineligible patients, with response rates of approximately 30-40% in heavily pretreated patients 2
- High-dose dexamethasone pulses may provide temporary responses in 30-50% of refractory patients, but should be used cautiously given prior steroid exposure 2
Rescue Therapy
- IVIG 1 g/kg as a single dose, and high-dose methylprednisolone 1 g IV daily × 3 days, are recommended for acute bleeding rescue therapy 4
- Platelet transfusion is only recommended for life-threatening hemorrhage, preferably combined with IVIG 4